E-Therapeutics Plc Company Profile - Aug 10, 2011 by WrightReports

VIEWS: 68 PAGES: 9

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   E-Therapeutics Plc
                                                                                           440 Wheelers Farms Road
                                                                                           Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in Pounds Sterling

                                  Wright Quality Rating:LLNN                                  Key Data

   e-Therapeutics plc (e-Therapeutics) is a United Kingdom-based company. The                 Ticker:
   Company is engaged in the discovery and development of drugs predominantly using           ETX
   its network analysis technology. The company possesses methods for discovering
   bioactive compounds, de-risking candidates against efficacy and safety, discovering        2009 Sales:
   combinations of compounds with specific therapeutic effects, and discovering
                                                                                              67,000
   indications for existing compounds. e-Therapeutics is developing candidate medicines
   in anti-infectives, depression, respiratory disorders, atherosclerosis, pain and cancer.
   Its medicines include ETX1153a: Mersanex, the antidepressant (ETS6103: Viotra),            Major Industry:
   ETX9101 (Orovair), ETX6107, ETX6218 and ETS2101. The Company has one                       Drugs, Cosmetics & Health
   subsidiary, InRotis Technologies Limited.                                                  Care
                       Stock Chart                                      Officers
                                                               Non Executive Chairman         Sub Industry:
                                                                Prof. Oliver F. W. James      Ethical Drug Manufacturers

                                                           Executive Director & Chief         Country:
                                                                   Executive                  United Kingdom
                                                             Prof. Malcolm P. Young
                                                                                              Currency:
                                                                Chief Financial Officer       Pounds Sterling
                                                                  Dr. Daniel W. Elger
                                                                                              Fiscal Year Ends:
                                                                     Secretary
                                                                                              January
                                                                   Sean T. Nicolson

                                                                                              Employees
                                                                                              16

                                                                                              Exchanges:
                                                                                              LON

                      
								
To top